Is JPMorgan Chase a Buy After Its Latest Earnings Report?

JPMorgan delivered a strong Q2: net revenue slightly above $57.3B (+28% YoY) and GAAP net income up 41% to nearly $21.2B ($7.70/share), both well ahead of consensus ($50.6B revenue, $5.55/share). Investment banking drove results, with CIB net revenue up 27% to nearly $24.9B and a 45% jump in investment banking activity. For 2026, management raised net interest income to ~$96.5B (ex-capital markets) from $95B and increased expenses to $107.5B from $105B; shares gained nearly 3% on Tuesday.

Analysis

JPM is reinforcing the market’s preference for “fee + balance sheet” compounders over plain-vanilla lenders. The key mechanism is operating leverage: when capital-markets activity is strong, the earnings mix shifts toward higher-margin fee income, which can mask slower spread income and justify a premium versus peers with more rate sensitivity.

The second-order implication is relative, not absolute. Money-center banks with diversified platforms should see a wider quality premium versus regional banks and any lender still fighting deposit costs or credit normalization. If this tape holds, the better read-through for NDAQ is not direct earnings lift but a healthier issuance/secondary backdrop; that benefit tends to show up later and is usually smaller than the initial move in the lead bank.

The contrarian risk is that investors may be extrapolating a peak-ish capital-markets environment. If volatility falls, underwriting slows, or expense discipline slips, the uplift can fade fast over the next 1-3 months. Structurally, JPM’s scale still supports outperformance over 6-18 months, but the near-term setup looks more like a quality rerating than a step-change in fundamentals.

The Visa share monetization is a one-off capital event, not recurring earnings power. Treat it as a balance-sheet/capital-return enhancer, not a reason to chase V; the better conclusion is that JPM can keep returning capital without stressing its core model.

Key Decisions for Investors

• Long JPM on any 2-3% post-earnings pullback; 1-3 month target is relative outperformance, not a heroic absolute move. Use a stop if guidance for NII or expenses is revised down next quarter.
• Pair trade: long JPM / short KRE for the next 1-3 months. Thesis is widening quality premium as fee-heavy money-center banks outperform regional lenders if credit stays benign; cover if KRE starts to outgrow JPM on deposit/NII strength.
• Small tactical long NDAQ only if equity issuance and underwriting activity remain elevated into the next monthly tape. This is a lower-conviction second-order beneficiary; size it small and exit if capital-markets volumes normalize.
• Do not add V on the Visa share exchange read-through alone. Treat that gain as non-recurring; only revisit V if payments volume or take-rate data improve independently.